Summary
51.67 -0.29(-0.55%)05/17/2024
Exact Sciences Corp. (EXAS)
Exact Sciences Corp. (EXAS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -3.02 | 3.37 | -13.87 | 0.47 | -5.96 | -10.42 | -40.25 | 309.40 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 61.41 | |
| Open | 63.36 | |
| High | 63.79 | |
| Low | 61.33 | |
| Volume | 1,652,911 | |
| Change | -1.91 | |
| Change % | -3.02 | |
| Avg Volume (20 Days) | 1,674,093 | |
| Volume/Avg Volume (20 Days) Ratio | 0.99 | |
| 52 Week Range | 56.05 - 100.77 | |
| Price vs 52 Week High | -39.06% | |
| Price vs 52 Week Low | 9.56% | |
| Range | -3.08 | |
| Gap Up/Down | -0.48 | |
Fundamentals | ||
| Market Capitalization (Mln) | 9,730 | |
| EBIDTA | -108,443,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -1.0700 | |
| WallStreet Target Price | 86.71 | |
| Book Value | 17.0390 | |
| Earnings Per Share | -1.3100 | |
| EPS Estimate Current Quarter | -0.4700 | |
| EPS Estimate Next Quarter | -0.2300 | |
| EPS Estimate Current Year | -1.0700 | |
| EPS Estimate Next Year | -0.0600 | |
| Diluted EPS (TTM) | -1.3100 | |
| Revenues | ||
| Profit Marging | -0.0948 | |
| Operating Marging (TTM) | -0.1512 | |
| Return on asset (TTM) | -0.0315 | |
| Return on equity (TTM) | -0.0776 | |
| Revenue TTM | 2,534,840,064 | |
| Revenue per share TTM | 13.9980 | |
| Quarterly Revenue Growth (YOY) | 0.0580 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 1,509,885,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.1191 | |
| Revenue Enterprise Value | 5.8937 | |
| EBITDA Enterprise Value | 503.1228 | |
| Shares | ||
| Shares Outstanding | 184,530,000 | |
| Shares Float | 183,234,322 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.05 | |
| Insider (%) | 0.98 | |
| Institutions (%) | 82.52 | |
05/17 06:27 EST - investorplace.com
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024
The ARK Innovation ETF (NYSEARCA: ARKK ) has come under the spotlight recently, and there are three Cathie Wood stocks to buy with strong buy ratings for investors to consider in May this year. One of the key characteristics of the ARK Innovation ETF is its concentrated portfolio, typically holding between 35 to 55 stocks.
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024
The ARK Innovation ETF (NYSEARCA: ARKK ) has come under the spotlight recently, and there are three Cathie Wood stocks to buy with strong buy ratings for investors to consider in May this year. One of the key characteristics of the ARK Innovation ETF is its concentrated portfolio, typically holding between 35 to 55 stocks.
05/10 03:00 EST - businesswire.com
The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences' Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients
LONDON--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK's National Institute for Health and Care Excellence (NICE) has recommended the expanded use of the Oncotype DX Breast Recurrence Score® test to more effectively target chemotherapy treatment for women who have hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), early-stage breast cancer involving up to three positive nodes and.
The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences' Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients
LONDON--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK's National Institute for Health and Care Excellence (NICE) has recommended the expanded use of the Oncotype DX Breast Recurrence Score® test to more effectively target chemotherapy treatment for women who have hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), early-stage breast cancer involving up to three positive nodes and.
05/09 12:05 EST - zacks.com
Exact Sciences (EXAS) Q1 Revenues Rise Y/Y, Gross Margin Down
Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences' (EXAS) first-quarter top line.
Exact Sciences (EXAS) Q1 Revenues Rise Y/Y, Gross Margin Down
Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences' (EXAS) first-quarter top line.
05/08 19:06 EST - zacks.com
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.42 per share a year ago.
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.42 per share a year ago.
05/08 17:00 EST - investors.com
Exact Sciences Stock, A Cathie Wood Darling, Tumbles On Wide Quarterly Losses
Exact Sciences stock tumbled late Wednesday after the Cologuard-maker reported wide losses, though sales came in ahead of expectations.
Exact Sciences Stock, A Cathie Wood Darling, Tumbles On Wide Quarterly Losses
Exact Sciences stock tumbled late Wednesday after the Cologuard-maker reported wide losses, though sales came in ahead of expectations.
05/07 08:00 EST - businesswire.com
Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences to present strategies and advancements for improving colorectal cancer screening rates and outcomes during Digestive Disease Week® 2024.
Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences to present strategies and advancements for improving colorectal cancer screening rates and outcomes during Digestive Disease Week® 2024.
05/01 06:00 EST - businesswire.com
Exact Sciences to Participate in May Investor Conference
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 15, 2024 at 4:40 p.m. ET The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. About Exact S.
Exact Sciences to Participate in May Investor Conference
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 15, 2024 at 4:40 p.m. ET The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. About Exact S.
04/24 19:16 EST - zacks.com
Exact Sciences (EXAS) Stock Drops Despite Market Gains: Important Facts to Note
In the latest trading session, Exact Sciences (EXAS) closed at $63.24, marking a -0.46% move from the previous day.
Exact Sciences (EXAS) Stock Drops Despite Market Gains: Important Facts to Note
In the latest trading session, Exact Sciences (EXAS) closed at $63.24, marking a -0.46% move from the previous day.
04/22 13:46 EST - zacks.com
Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?
Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.
Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?
Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.
04/17 19:21 EST - zacks.com
Why Exact Sciences (EXAS) Dipped More Than Broader Market Today
Exact Sciences (EXAS) concluded the recent trading session at $63.22, signifying a -1% move from its prior day's close.
Why Exact Sciences (EXAS) Dipped More Than Broader Market Today
Exact Sciences (EXAS) concluded the recent trading session at $63.22, signifying a -1% move from its prior day's close.
04/15 06:00 EST - businesswire.com
Exact Sciences Names Aaron Bloomer as New Chief Financial Officer
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience. He previously held leadership positions at Baxter International and 3M, where he helped improve financial results, drove operational rigor, led strategic growth initiatives,.
Exact Sciences Names Aaron Bloomer as New Chief Financial Officer
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience. He previously held leadership positions at Baxter International and 3M, where he helped improve financial results, drove operational rigor, led strategic growth initiatives,.
04/11 06:00 EST - businesswire.com
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS) (the “Company”), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered into privately negotiated exchange and purchase agreements (the “Agreements”) with certain holders of the Company's 0.3750% Convertible Senior Notes due 2028 (the “Existing Notes”). Pursuant to the Agreements, the Company has agreed to issue to the holders $620.7 million aggregate principal amount of a.
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS) (the “Company”), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered into privately negotiated exchange and purchase agreements (the “Agreements”) with certain holders of the Company's 0.3750% Convertible Senior Notes due 2028 (the “Existing Notes”). Pursuant to the Agreements, the Company has agreed to issue to the holders $620.7 million aggregate principal amount of a.
04/10 16:31 EST - zacks.com
3 Buy-Rated Stocks Flexing Relative Strength
While the market has taken a small breather as of late, there have been many big-time winners throughout the last month, including these three. Analysts are bullish on their outlooks, with all three carrying a favorable Zacks Rank.
3 Buy-Rated Stocks Flexing Relative Strength
While the market has taken a small breather as of late, there have been many big-time winners throughout the last month, including these three. Analysts are bullish on their outlooks, with all three carrying a favorable Zacks Rank.
04/08 12:05 EST - businesswire.com
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test. These results validate the sensitivity and specificity of the company's multi-biomarker class approach across a broad range of cancer types, including the m.
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test. These results validate the sensitivity and specificity of the company's multi-biomarker class approach across a broad range of cancer types, including the m.
04/08 06:00 EST - businesswire.com
Exact Sciences Schedules First Quarter 2024 Earnings Call
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2024 webcast & conference call details Date: Wedn.
Exact Sciences Schedules First Quarter 2024 Earnings Call
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2024 webcast & conference call details Date: Wedn.
04/05 16:16 EST - investorplace.com
The 3 Best Cathie Wood Stocks to Buy in April 2024
Full disclosure, I'm not a tremendous fan of Cathie Wood. Generally, I think she makes some terrible picks.
The 3 Best Cathie Wood Stocks to Buy in April 2024
Full disclosure, I'm not a tremendous fan of Cathie Wood. Generally, I think she makes some terrible picks.
04/04 10:15 EST - fool.com
1 Beaten-Down Cathie Wood Stock to Buy and Hold
Exact Sciences' most important product is still driving top-line growth. The company is working on several other exciting diagnostic tests.
1 Beaten-Down Cathie Wood Stock to Buy and Hold
Exact Sciences' most important product is still driving top-line growth. The company is working on several other exciting diagnostic tests.
04/04 06:05 EST - businesswire.com
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
ROCHESTER, Minn. & MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences and Mayo Clinic advance precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients.
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
ROCHESTER, Minn. & MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences and Mayo Clinic advance precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients.
04/03 11:01 EST - zacks.com
Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising
Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.
Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising
Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.
04/02 13:03 EST - investors.com
Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales
Exact Sciences stock surged Tuesday after the company's colon cancer-screening rival, Freenome, unveiled the results of a pivotal study.
Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales
Exact Sciences stock surged Tuesday after the company's colon cancer-screening rival, Freenome, unveiled the results of a pivotal study.